Abstract
Colorectal cancer (CRC) is the most important cause of tumor-related fatalities around the world, and its distant metastasis is responsible for 40% of mortalities in the USA as well as around the world. CRC is not a single disease; it is rather an assortment of multiple cancers. Metastatic CRC develops from the relapse period after the therapy, where the cancer cells develop resistance. Due to the heterogeneous biology, clear descriptive study at molecular level about the mechanisms, which takes place during CRC invasion and proliferation, is necessary. These studies can help understand the factors affecting the increased risk of CRC progression and help deduce novel therapeutic strategies. This chapter includes the mechanism of EGFR and FGFR in CRC, which are common targets for therapy since they induce cell proliferation and cell division and inhibit apoptosis. Their overexpression in CRC is associated with metastasis including invasion and angiogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carraway IIIKL, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78(1):5–8
van der Geer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10(1):251–337
Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M, Croce CM (2005) WW domain–containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65(15):6764–6772
Fallon L, Bélanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI (3) K–Akt signalling. Nat Cell Biol 8(8):834
Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y (1998) c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12(23):3663–3674
Reddi H (2013) Mutations in the EGFR pathway: clinical utility and testing strategies. Clin Lab News 39:14–16
Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y (2014) BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer 14(1):802
Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam A, Lee J, Yarden Y, Libermann TA, Schlessinger J (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309(5967):418
Carpenter G, Lloyd K Jr, Cohen S (1978) Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 276(5686):409
Ushiro H, Cohen S (1980) Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 255(18):8363–8365
Harel A, Forbes DJ (2004) Importin beta: conducting a much larger cellular symphony. Mol Cell 16(3):319–330
Wang Y-N, Wang H, Yamaguchi H, Lee H-J, Lee H-H, Hung M-C (2010) COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem Biophys Res Commun 399(4):498–504
Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1(1):19–31
Karameris A, Kanavaros P, Aninos D, Gorgoulis V, Mikou G, Rokas T, Niotis M, Kalogeropoulos N (1993) Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas1: an immunohistological study of 63 cases. Pathol-Res Pract 189(2):133–137
Radinsky R (1995) Modulation of tumor cell gene expression and phenotype by the organ specific metastatic environment. Cancer Metastasis Rev 14(4):323–338
Spano J-P, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere J-F (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–108
Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, Mosnier JF (2005) Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207(2):156–163
Itoh N, Ohta H (2013) Roles of FGF20 in dopaminergic neurons and Parkinson’s disease. Front Mol Neurosci 6:15
Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG (2001) Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271(2):171–182
Silva PN, Altamentova SM, Kilkenny DM, Rocheleau JV (2013) Fibroblast growth factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation. J Biol Chem 288(24):17859–17870
Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3):235
Johnson DE, Williams LT (1992) Structural and functional diversity in the FGF receptor multigene family. Edition ed. Advances in cancer research. Elsevier, Burlington, pp 1–41
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM (2006) Receptor specificity of the fibroblast growth factor family the complete mammalian fgf family. J Biol Chem 281(23):15694–15700
Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N, Li X, Tang J, Lindberg R, Li Y (2009) Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci 106(34):14379–14384
Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R (2010) FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 285(8):5165–5170
Gonzalez AM, Hill DJ, Logan A, Maher PA, Baird A (1996) Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus. Pediatr Res 39(3):375
Kirikoshi H, Sagara N, Saitoh T, Tanaka K, Sekihara H, Shiokawa K, Katoh M (2000) Molecular cloning and characterization of human FGF-20 on chromosome 8p21. 3-p22. Biochem Biophys Res Commun 274(2):337–343
Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL, Sylander ED, Rittman B, Bendele A, Sartor RB (2002) A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 123(4):1151–1162
Visco V, Belleudi F, Marchese C, Leone L, Aimati L, Cardinali G, Kovacs D, Frati L, Torrisi MR (2004) Differential response to keratinocyte growth factor receptor and epidermal growth factor receptor ligands of proliferating and differentiating intestinal epithelial cells. J Cell Physiol 200(1):31–44
Jang J-H, Shin K-H, Park Y-J, Lee RJ, McKeehan WL, Park J-G (2000) Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res 60(15):4049–4052
Sato T, Oshima T, Yoshihara K, Yamamoto N, Yamada R, Nagano Y, Fujii S, Kunisaki C, Shiozawa M, Akaike M (2009) Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Rep 21(1):211–216
Takaishi S, Sawada M, Morita Y, Seno H, Fukuzawa H, Chiba T (2000) Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 267(2):658–662
Desnoyers L, Pai R, Ferrando R, Hötzel K, Le T, Ross J, Carano R, D’souza A, Qing J, Mohtashemi I (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27(1):85
Jang J-H (2005) Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis. Oncogene 24(5):945
Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun MA (1997) Novel juxtamembrane domain isoform of HER4/ErbB4 isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 272(42):26761–26768
Komuro A, Nagai M, Navin NE, Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278(35):33334–33341
Spano J, Fagard R, Soria J-C, Rixe O, Khayat D, Milano G (2005) Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16(2):189–194
Itoh N, Ornitz DM (2008) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237(1):18–27
Lindner V, Majack R, Reidy M (1990) Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 85(6):2004–2008
Halaban R (1996) Growth factors and melanomas. Semin Oncol 10:673–681
Bian X-W, Du L-L, Shi J-Q, Cheng Y-S, Liu F-X (2000) Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Anal Quant Cytol Histol 22(3):267–274
Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969
Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M (1993) Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53(21):5289–5296
Berger W, Setinek U, Mohr T, Kindas-Mügge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M (1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83(3):415–423
Gazzaniga P, Gandini O, Gradilone A, Silvestri I, Giuliani L, Magnanti M, Gallucci M, Saccani G, Frati L, Agliano A (1999) Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. Int J Oncol 14(6):1123–1130
Dellacono FR, Spiro J, Eisma R, Kreutzer D (1997) Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am J Surg 174(5):540–544
Huang X, Yu C, Jin C, Yang C, Xie R, Cao D, Wang F, McKeehan WL (2006) Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 45(12):934–942
Ramos C, Becerril C, Montaño M, GarcÃa-De-Alba C, RamÃrez R, Checa M, Pardo A, Selman M (2010) FGF-1 reverts epithelial-mesenchymal transition induced by TGF-β1 through MAPK/ERK kinase pathway. Am J Phys Lung Cell Mol Phys 299(2):L222–LL31
Jouanneau J, Plouet J, Moens G, Thiery JP (1997) FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. Oncogene 14(6):671
Kwabi-Addo B, Ozen M, Ittmann M (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11(4):709–724
Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M (1992) Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76(5):792–798
Nakao Y, Mitsuyasu T, Kawano S, Nakamura N, Kanda S, Nakamura S (2013) Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway. Int J Oncol 43(5):1377–1384
Matsuda Y, Ueda J, Ishiwata T (2012) Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Pathol Res Int 2012:574768
Liu R, Huang S, Lei Y, Zhang T, Wang K, Liu B, Nice EC, Xiang R, Xie K, Li J (2015) FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget 6(2):935
Sun C, Fukui H, Hara K, Zhang X, Kitayama Y, Eda H, Tomita T, Oshima T, Kikuchi S, Watari J (2015) FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells. BMC Cancer 15(1):333
Okada T, Murata K, Hirose R, Matsuda C, Komatsu T, Ikekita M, Nakawatari M, Nakayama F, Wakatsuki M, Ohno T (2013) Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci Rep 3:2899
Basu M, Mukhopadhyay S, Chatterjee U, Roy SS (2014) FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. J Biol Chem 289(3):1415–1428
Jarosz M, Robbez-Masson L, Chioni A-M, Cross B, Rosewell I, Grose R (2012) Fibroblast growth factor 22 is not essential for skin development and repair but plays a role in tumorigenesis. PLoS One 7(6):e39436
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2–16
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127
Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE (1998) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18(9):5042–5051
Schlessinger J, Lemmon MA (2006) Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 127(1):45–48
Ni C-Y, Murphy MP, Golde TE, Carpenter G (2001) γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294(5549):2179–2181
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6):1137–1149
Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306(5701):1506–1507
Moosa S, Wollnik B (2016) Altered FGF signalling in congenital craniofacial and skeletal disorders. Sem Cell Dev Biol: Elsevier 53:115–125
Batzer A, Rotin D, Urena J, Skolnik E, Schlessinger J (1994) Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14(8):5192–5201
Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R, Ullrich A, Skolnik E, Bar-Sagi D, Schlessinger J (1992) The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70(3):431–442
Hallberg B, Rayter SI, Downward J (1994) Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem 269(6):3913–3916
Nandan MO, Yang VW (2011) An update on the biology of RAS/RAF mutations in colorectal cancer. Curr Color Cancer Rep 7(2):113–120
Ubeda M, Vallejo M, Habener JF (1999) CHOP enhancement of gene transcription by interactions with Jun/Fos AP-1 complex proteins. Mol Cell Biol 19(11):7589–7599
Carpenter C, Duckworth B, Auger K, Cohen B, Schaffhausen B, Cantley L (1990) Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 265(32):19704–19711
Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1(1):42–55
Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6):1075
Mattoon DR, Lamothe B, Lax I, Schlessinger J (2004) The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol 2(1):24
Shaw RJ, Cantley LC, Ras PI (2006) (3) K and mTOR signalling controls tumour cell growth. Nature 441(7092):424
Chattopadhyay A, Vecchi M, Ji Q-S, Mernaugh R, Carpenter G (1999) The role of individual SH2 domains in mediating association of phospholipase C-γ1 with the activated EGF receptor. J Biol Chem 274(37):26091–26097
Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109(9):1139–1142
Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273(15):8890–8896
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402(6764):884
Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A (2001) Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20(13):1594
Gschwind A, Prenzel N, Ullrich A (2002) Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 62(21):6329–6336
Carpenter G (2000) EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Sci STKE 2000(15):pe1–pe
Huang F, Goh LK, Sorkin A (2007) EGF receptor ubiquitination is not necessary for its internalization. Proc Natl Acad Sci 104(43):16904–16909
Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y (1998) Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17(12):3385–3397
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767
Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ (2017) Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 18(1):197
Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10(1):13–27
Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T (2013) Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229(3):441–448
Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073–2087 e3
Barresi V, Castorina S, Musso N, Capizzi C, Luca T, Privitera G, Condorelli DF (2017) Chromosomal instability analysis and regional tumor heterogeneity in colon cancer. Cancer Genet 210:9–21
Pino MS, Chung DC (2010) The chromosomal instability pathway in colon cancer. Gastroenterology 138(6):2059–2072
Grady WM (2004) Genomic instability and colon cancer. Cancer Metastasis Rev 23(1–2):11–27
Rajagopalan H, Lengauer C (2004) Aneuploidy and cancer. Nature 432(7015):338
Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR (2002) Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci 99(14):9433–9438
Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH (2001) Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3(4):433
Leslie A, Carey F, Pratt N, Steele R (2002) The colorectal adenoma–carcinoma sequence. Br J Surg 89(7):845–860
Worthley DL, Leggett BA (2010) Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 31(2):31
Lao VV, Grady WM (2011) Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 8(12):686
Feinberg AP (2004) The epigenetics of cancer etiology. Sem Cancer Biol: Elsevier 14:427–432
de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt PA, Weijenberg MP, van Engeland M (1909) Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Prevent Biomark 1055–9965. EPI-09-0289
Van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51(6):797–802
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38(7):787
Ahuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, Baylin SB, Issa J-PJ (1997) Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 57(16):3370–3374
de Castro-Carpeño J, Belda-Iniesta C, Sáenz EC, Agudo EH, Batlle JF, Barón MG (2008) EGFR and colon cancer: a clinical view. Clin Transl Oncol 10(1):6–13
Kim HA, Lee RA, Hwang DY, Park SH (2005) The significances of EGFR overexpression in colorectal cancer. J Kor Soc Coloproctol 21(1):36–41
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8(12):1197–1206
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non–small-cell lung cancer. J Natl Cancer Inst 96(15):1133–1141
Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, Ohira M, Hirakawa K, Mori M (2005) Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11(4):1368–1371
Oh B-Y, Lee R-A, Chung S-S, Kim KH (2011) Epidermal growth factor receptor mutations in colorectal cancer patients. J Kor Soc Coloproctol 27(3):127–132
Tsuchida N, Ohtsubo E, Ryder T (1982) Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. Science 217(4563):937–939
Burmer GC, Loeb LA (1989) Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci 86(7):2403–2407
Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruïne AP, Goldbohm RA, van den Brandt PA (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24(4):703–710
Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Prevent Biomark 9(11):1193–1197
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C (2009) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28(3):466–474
Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N (2015) Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 15(1):340
Zhang S, Yu D (2010) PI (3) king apart PTEN’s role in cancer. Clin Cancer Res 16(17):4325–4330
Smitha C, Suresh BM, Linu J, Lakshmaiah K, Govind BK, Lokanatha D, Pretesh R (2017) Patterns and the occurrence of KRAS mutations in metastatic colorectal cancers—a study from Indian Regional Cancer Centre. Indian J Surg Oncol 8(4):511–513
Sithanandam G, Kolch W, Duh F, Rapp U (1990) Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 5(12):1775–1780
Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K, Rapp UR (1992) B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 7(4):795–799
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65(14):6063–6069
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418(6901):934
Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French A, Westra J, Frebourg T, Espin E, Armengol M (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41(9):664–668
Loughrey M, Waring P, Tan A, Trivett M, Kovalenko S, Beshay V, Young M-A, McArthur G, Boussioutas A, Dobrovic A (2007) Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Familial Cancer 6(3):301–310
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101(4):715
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8):753–762
Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P (2017) Immunohistochemistry with Anti-BRAF V600E (VE1) mouse monoclonal antibody is a sensitive method for detection of the BRAF V600E mutation in colon cancer: evaluation of 120 cases with and without KRAS mutation and literature review. Pathol Oncol Res:1–11
Bond CE, Liu C, Kawamata F, McKeone DM, Fernando W, Jamieson S, Pearson S-A, Kane A, Woods SL, Lannagan TR (2017) Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia. Epigenetics 13:01–20
Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B, Segelov E (2004) PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23(2):617
Zhou X-P, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, De la Chapelle A, Aaltonen LA, Eng C (2002) PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161(2):439–447
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64(9):3014–3021
Jhawer M, Goel S, Wilson AJ, Montagna C, Ling Y-H, Byun D-S, Nasser S, Arango D, Shin J, Klampfer L (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953–1961
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851–1857
De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG (1998) Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28(4):971–979
Ohgino K, Soejima K, Yasuda H, Hayashi Y, Hamamoto J, Naoki K, Arai D, Ishioka K, Sato T, Terai H (2014) Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer 83(1):90–96
Zammit C, Coope R, Gomm J, Shousha S, Johnston C, Coombes R (2002) Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer. Br J Cancer 86(7):1097
Acevedo VD, Ittmann M, Spencer DM (2009) Paths of FGFR-driven tumorigenesis. Cell Cycle 8(4):580–588
Sahlin P, Tarnow P, Martinsson T, Stenman G (2009) Germline mutation in the FGFR3 gene in a TWIST1-negative family with Saethre-Chotzen syndrome and breast cancer. Genes Chromosom Cancer 48(3):285–288
Tomlinson D, Knowles M, Speirs V (2012) Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 130(12):2857–2866
Jang J-H, Shin K-H, Park J-G (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61(9):3541–3543
Dutt A, Salvesen HB, Chen T-H, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci 105(25):8713–8717
Pollock P, Gartside M, Dejeza L, Powell M, Mallon MA, Davies H, Mohammadi M, Futreal P, Stratton M, Trent J (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26(50):7158
Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, Zheng B, Cao X, Sun M-H, Fu H (2010) The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol 17(12):3354–3361
Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M (1999) Structural basis for FGF receptor dimerization and activation. Cell 98(5):641–650
Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ, Fidler IJ, Langley RR (2008) Modification of the primary tumor microenvironment by transforming growth factor α-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol 173(1):205–216
Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8(1):3–9
Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59(2):S21–SS6
Harris AL (2002) Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47
Huo Wu XJ, Cheng X, He Y, Hu L, Wu H, Ye F, Zhao R (2016) Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway. Oncotarget 7(45):73402
Sommers CL, Gelmann EP, Kemler R, Cowin P, Byers SW (1994) Alterations in β-catenin phosphorylation and plakoglobin expression in human breast cancer cells. Cancer Res 54(13):3544–3552
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27(16):2622–2629
Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri M, La Farina M, Albanese I, Dardanoni G, Salerno S (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13(9):1438–1446
Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, Xia D, Xu E, Lai M, Wu Y (2018) Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev 1–15
Huang L, Wen C, Yang X, Lou Q, Wang X, Che J, Chen J, Yang Z, Wu X, Huang M (2018) PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. Cell Death Dis 9(3):271
Lorusso G, Rüegg C (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130(6):1091–1103
Sleeman JP, Christofori G, Fodde R, Collard JG, Berx G, Decraene C, Rüegg C (2012) Concepts of metastasis in flux: the stromal progression model. Sem Cancer Biol: Elsevier 22:174–186
Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H (2013) FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res 73(19):5926–5935
Roidl A, Berger H-J, Kumar S, Bange J, Knyazev P, Ullrich A (2009) Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 15(6):2058–2066
Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Res 62(3):840–847
Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Sem Cell Dev Biol: Elsevier 19:294–308
Bokemeyer C, Bondarenko I, Hartmann J, De Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7):1535–1546
Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H (2005) Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 27(2):317–325
Corcoran RB, André T, Atreya CE, Schellens JH, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E-mutant colorectal Cancer. Cancer Discov 8:428–443
Tessitore A, Bruera G, Mastroiaco V, Cannita K, Cortellini A, Cocciolone V, Dal Mas A, Calvisi G, Zazzeroni F, Ficorella C (2018) KRAS and two rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Hum Pathol 74:178–182
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S (2018) Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open 3(2):e000303
Matsuda Y, Ishiwata T, Yamahatsu K, Kawahara K, Hagio M, Peng W-X, Yamamoto T, Nakazawa N, Seya T, Ohaki Y (2011) Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer. Cancer Lett 309(2):209–219
Rothe C, Urlinger S, Löhning C, Prassler J, Stark Y, Jäger U, Hubner B, Bardroff M, Pradel I, Boss M (2008) The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376(4):1182–1200
Zheng S-J, Zheng S-P, Huang F-Y, Jiao C-L, Wu R-L (2007) Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model. World J Gastroenterol: WJG 13(17):2484
Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X (2010) Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 145(1):17–25
Turkington R, Longley D, Allen W, Stevenson L, McLaughlin K, Dunne P, Blayney J, Salto-Tellez M, Van Schaeybroeck S, Johnston P (2014) Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis 5(2):e1046
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Lerchenmüller C, Kahl C, Seipelt G (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065–1075
Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony M, O’Neil B, Shaw J, Polite B, Hochster H, Atkins J (2014) 501O CALGB/SWOG 80405: phase III trial of irinotecan/5-fu/leucovorin (folfiri) or oxaliplatin/5-fu/leucovorin (mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mcrc). Ann Oncol 25(Suppl 4):mdu438 13
Riesco-Martinez MC, Sanchez-Torre A, Garcia-Carbonero R (2017) Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. Expert Opin Investig Drugs 26(11):1295–1305
Mori S, Tran V, Nishikawa K, Kaneda T, Hamada Y, Kawaguchi N, Fujita M, Takada YK, Matsuura N, Zhao M (2013) A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. PLoS One 8(2):e57927
Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM (2012) FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 18(14):3780–3790
Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A (2016) Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 7:13665
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Dariya, B., Merchant, N., Aliya, S., Alam, A., Nagaraju, G.P. (2018). EGFR and FGFR in Growth and Metastasis of Colorectal Cancer. In: Nagaraju, G. (eds) Role of Tyrosine Kinases in Gastrointestinal Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-13-1486-5_11
Download citation
DOI: https://doi.org/10.1007/978-981-13-1486-5_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-1485-8
Online ISBN: 978-981-13-1486-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)